Kristen Rohr

Partner, New York

Biography

Overview

Kristen Rohr is a partner in the Mergers and Acquisitions Practice Group, and is resident in the New York office. Ms. Rohr focuses on the representation of corporate clients and private equity funds in connection with domestic and global mergers, acquisitions and equity investments in a broad range of industries.

Bars and Courts
New York State Bar
Education
JD/MBA
University of Toronto
BA
McGill University
International Program
Institut d'Études Politiques de Paris
Sciences Po
Languages
English

Experience

Qatar Investment Authority, 2020
Representation of Qatar Investment Authority in its co-investment with a consortium led by Tencent Holdings Ltd. and its affiliate Tencent Music Entertainment Group (NYSE: TME) in the acquisition of a 10% stake in Universal Music Group, from Vivendi S.A.

Newmont Mining Corporation, 2019
Representation of Newmont Mining Corporation (NYSE: NEM), a gold and copper producer based in the United States with operations worldwide, in its US$10 billion acquisition of Goldcorp Inc. (NYSE: GG, TSX: G), a Canadian senior gold producer.

NTT DATA, Inc., 2019
Representation of NTT DATA, Inc., a recognized leader in global technology services, in its acquisition of Net eSolutions Corporation, a provider of digital design and transformation services for U.S. Department of Health and Human Services agencies.

Roark Capital Group, 2019
Representation of Roark Capital Group and Inspire Brands, Inc., a global multi-brand restaurant company, in the acquisition of Jimmy John's LLC, a fast food sandwich restaurant chain.

Seaspan Corporation, 2018
Representation of Seaspan Corporation (NYSE: SSW), the world's largest independent containership owner-operator, in its acquisition of the remaining 89% of Greater China Intermodal Investments LLC it did not previously own from affiliates of The Carlyle Group and other minority owners at an implied enterprise value of US$1.6 billion.

Roivant Sciences, 2018
Representation of Roivant Sciences Ltd., a biopharmaceutical drug development company, in the launch of Genevant Sciences Ltd., a joint venture with Arbutus Biopharma Corporation (NASDAQ: ABUS), focused on the discovery, development and commercialization of a broad range of RNA-based therapeutics enabled by Arbutus' proprietary lipid nanoparticle (LNP) and ligand conjugate delivery technologies.

Roivant Sciences, 2017
Representation of Roivant Sciences in its US$1.1 billion equity financing from SoftBank Vision Fund.

Fortis Inc., 2016
Representation of Fortis Inc., Canada's largest publicly-owned distribution utility, in its US$11.3 billion acquisition of ITC Holdings Corp., an electric transmission company operating in the Great Lakes and Great Plains regions.

Iconix, 2016
Representation of Iconix Brand Group, Inc., a NASDAQ-listed consumer brand management company, in its US$100 million sale of intellectual property assets and licenses primarily related to the Sharper Image brand in the United States, Latin America, China, India and Israel.

Hovensa, 2016
Representation of Hovensa L.L.C., a US Virgin Islands company and a joint venture formed by Hess Corp. and Petróleos de Venezuela, in the sale of substantially all of its petroleum terminalling assets pursuant to Sections 363 and 365 of the Bankruptcy Code, to a subsidiary of ArcLight Capital Partners, LLC.